Miao Liu

This study identifies cryptotanshinone as a potential antitumor compound in bladder cancer, showing immunomodulatory effects through modulation of the cGAS-STING-IFN-I-JAK-STAT-IFIT signaling pathway.

This paper uses AI to identify and validate non-coding regulatory variants affecting RHD expression, showing strong agreement between predictions and experimental results.

This study develops a computer-aided designed peptide degrader, Cadd4, which reduces PCSK9 levels and lowers LDL-C in mice and human liver tissue without toxicity.

This paper discovers and characterizes SH6, a small molecule degrader of ZBTB7A that increases fetal hemoglobin expression in erythroid cells and shows therapeutic potential for β-hemoglobinopathies.

This study identifies a new IMiD-independent drug targeting SALL4's ZFC4 domain, leading to significant tumor growth inhibition in vivo.

The paper identifies a compound that degrades both SALL4 isoforms, overcoming IMiD limitations in liver cancer treatment.

This study shows that SALL4 can be induced in cancer cells to make them dependent on it, enabling targeted therapy with drugs like DAC and ENT.